You searched for "papillomatous"

55 results found

Treat-and-extend regimen in treatment of patients with type 3 neovascularisation

Type 3 neovascularisation, also known as retinal angiomatous proliferation is a distinct subtype of neovascular AMD characterised by intraretinal neovascularisation. This retrospective study included 17 eyes diagnosed with type 3 neovascularisation who were changed from pro-re-nata (PRN) based treatment regime...

Atrophy and anti-VEGF

The aim of this study was to investigate treatment factors, along with ocular and systemic factors for their association with macular atrophy (MA) incidence in eyes with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF aflibercept or ranibizumab according to...

Vision loss during Eylea treatment for AMD

This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....

Insects, swelling and sight loss: a case of orbital inflammatory syndrome

Despite being the most common cause of painful orbital mass in adults and the third most common orbital disease, orbital inflammatory syndrome still proves to be a difficult ocular condition to diagnose, treat, and manage. A 41-year-old lady presented to...

Understanding the inequalities of ophthalmic care for Indigenous people in a first world country

Aboriginal Australians have faced numerous challenges over the past centuries. Here in this article, Edward Saxton highlights why there are inequalities of ophthalmic care in Australia and why this has led to increased levels of blindness in Aboriginal people relative...

Treatment of diabetic macular oedema

Diabetic macular oedema (DMO) is a common complication associated with diabetic retinopathy, and the most common cause of visual impairment in diabetes [1]. With predicted rising levels of diabetes (in England by 2025 the estimated population with diabetes will be...

Intravitreal aflibercept for retinal angiomatous proliferation (RAP)

In this prospective study the authors present the visual and anatomical outcome of patients with RAP lesions who were treated with intravitreal aflibercept. The study cohort of 46 patients reached study completion at week 96. They were all Caucasians, with...

Retinal pigment epithelium tears

In this paper the authors review the current knowledge of retinal pigment epithelium (RPE) tears. Although rare these can cause loss of visual acuity. They can occur spontaneously in pigment epithelial detachment (PED) due to occult choroidal neovascularisation (CNV), retinal...

Toxoplasmosis and the associated retinochoroiditis: important facts and when to treat

Annie SeeWah Tung provides an overview of toxoplasmosis retinochoroiditis, including guidance on which cases should be treated and the treatment options. Toxoplasmosis retinochoroiditis is an infectious condition that is characterised by retinochoroidal lesions commonly in the posterior pole and is...

Clinical relevance of the anatomic classification of neovascular age-related macular degeneration

The author explains why an OCT-based classification of neovascular AMD is needed and how these neovascular subtypes may help to predict patients’ long-term visual outcome. Age-related macular degeneration (AMD) is a chronic and progressive neurodegenerative process involving the macula in...

What’s next in retinal imaging? Faster, deeper and full-on

Fast-evolving technological leaps are opening the way toward clinically useful ocular coherence angiography, generating 3-dimensional microvasculature maps without intravenous dye injection, as well as whole-eye imaging, handheld patient-operated optical coherence tomography (OCT) devices and, for challenging vitreoretinal procedures, integrated intraoperative...

Neovascular AMD: fresh recommendations underline standards of best practice

The management of neovascular age-related macular degeneration (nAMD) has advanced dramatically over the past seven years, with the introduction of targeted new therapies that successfully maintain or improve vision in a majority of affected individuals. It’s a fast moving field,...